Premium Content VIDEO ASCO

Pembrolizumab doubles time to disease progression in patients with advanced colorectal cancer with specific DNA mutations

'Immunotherapies like pembrolizumab have proved to be effective as second-line treatments for advanced disease. Now,... we are starting to see significant efficacy for immunotherapies as first-line treatment for advanced cancers with specific genetic signatures...,' said ASCO President Howard Burris

Please sign in or register for FREE

No comments yet.